- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-Q Quarterly report
- 4.3 Waiver of Rights Upon Issuance of Other Securities Dated July 29, 2009
- 4.6 Waiver of Rights Upon Issuance of Other Securities Dated August 3, 2009
- 10.1 First Amendment to Employment Agreement Dated July 2, 2009 for Garo Armen
- 10.2 First Amendment to Employment Agreement Dated July 2, 2009 for Shalini Sharp
- 10.3 First Amendment to Employment Agreement Dated July 2, 2009 for Karen Valentine
- 10.4 First Amendment to Employment Agreement Dated July 2, 2009 for Kerry Wentworth
- 10.5 Amended and Restated License Agreement
- 10.6 Notice of Assignment of Amended and Restated License Agreement
- 10.7 Supply Agreement
- 31.1 Certification of CEO Pursuant to Section 302
- 31.2 Certification of CFO Pursuant to Section 302
- 32.1 Certification of CEO and CFO Pursuant to Section 906
Exhibit 32.1
Certification
Pursuant to 18 U.S.C. Section 1350,
As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q of Antigenics Inc. (the “Company”) for the quarterly period ended September 30, 2009 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned to his/her knowledge hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
(i) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(ii) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ GARO H. ARMEN, PH.D. |
Garo H. Armen, Ph.D. Chief Executive Officer |
/s/ SHALINI SHARP |
Shalini Sharp Chief Financial Officer |
Date: November 9, 2009
A signed original of this written statement required by Section 906 has been provided to Antigenics Inc. and will be retained by Antigenics Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
The foregoing certification is being furnished to the Securities and Exchange Commission as an exhibit to the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2009 and should not be considered filed as part of the Quarterly Report on Form 10-Q.